

6714/05

PATENT

DAE
5
JRW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Puls, Stefan M., et al.
 Appl. No. TRADEMA~~10~~782,375
 Filed : February 18, 2004
 Title : PARKIN INTERACTING POLYPEPTIDES
 AND METHODS OF USE
 Grp./A.U. : 1645
 Examiner: Not Yet Assigned

Customer No.: 41552
 Confirmation No.: 3578

CERTIFICATE OF MAILING BY EXPRESS MAIL(37)
 CFR § 1.10)

"Express Mail" Mailing Label Number EV643842954US

I hereby certify that this paper or fee is being deposited with the
 United States Postal Service "Express Mail Post Office to
 Addressee" service under 37 CFR § 1.10 on the date indicated
 above and is addressed to Commissioner for Patents, P.O. Box
 1450, Alexandria, VA 22313-1450 on Jul 12, 2005.

Sarah Nunez

Mail Stop Petition
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Petition for Revival of an Application for Patent Abandoned Unintentionally.

- Applicant is entitled to small entity status under 37 CFR 1.27.
 Also attached: Copy of the response to Missing Parts as originally filed on October 8, 2004; Copy of Notice of Abandonment

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	10	25	0	\$25.00 =	\$0.00
Independent Claims	1	4	0	\$100.00 =	\$0.00
Multiple dependent claims newly presented					\$0.00
Fee for Petition to Revive					\$750.00
Total of Above Calculations					\$750.00

- Please charge my Deposit Account No. 502624 in the amount of \$750.00. An additional copy of this transmittal sheet is submitted herewith.
- The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment, to Deposit Account No. 502624, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP

Deborah L. Cadena


Deborah L. Cadena
 Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
 San Diego, CA 92122

858.535.9001 DLC:mls

Facsimile: 858.597.1585

Date: July 5, 2005



Docket No.: 066783-0145

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al.
Appl. No. : 10/782,375
Filed : February 18, 2004
Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE

Grp./A.U. : 1645
Examiner: Not Yet Assigned

Customer No.: 41552
Confirmation No.: 3578
CERTIFICATE OF MAILING BY EXPRESS MAIL(37)
CFR § 1.10)

"Express Mail" Mailing Label Number EV643842954US
I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office to
Addressee" service under 37 CFR § 1.10 on the date indicated
above and is addressed to Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on JUL 12, 2005.


Sarah Nunez

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 C.F.R. §1.137(b)**

The above-identified application became abandoned because the response to Missing Parts was not timely received by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

Applicants hereby petition for revival of this application. Since this application was filed on February 18, 2004, no terminal disclaimer is required.

The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 C.F.R. 1.137(b) was unintentional.

The petition fee of \$750.00 required by 37 C.F.R. § 1.17(m) is enclosed herewith. Please charge my Deposit Account No. 502624 in the amount of \$750.00 to cover the petition fee.

07/15/2005 MAHMED1 00000049 502624 10782375

01 FC:2453 750.00 DA

Serial No. 10/782,375

Applicants are simultaneously filing a copy of the response to Missing Parts as originally filed on October 8, 2004.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:mls
Facsimile: 858.597.1585
Date: July 12, 2005



COPY

Docket No.: 066783-0145

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al. Customer No.: 41552
Appl. No. : 10/782,375 Confirmation No.: 3578
Filed : February 18, 2004
Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE
Grp./A.U. : Unassigned
Examiner: : Unassigned

CERTIFICATE OF MAILING BY EXPRESS MAIL(37 CFR § 1.10)

"Express Mail" Mailing Label Number EV 540 267 677 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Oct 8, 2004.

Carrie Casey

RESPONSE TO NOTICE TO FILE MISSING PARTS

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are in receipt of the Notice to File Missing Parts mailed August 13, 2004, the following are provided:

1. A copy of the Notice to File Missing Parts.
2. Declaration.
3. Power of Attorney for Patent Application by Assignee.
4. Statement Under 37 C.F.R. § 3.73(b) and a copy of the executed assignment.
5. Small Entity Statement.
6. Paper Copy of Sequence Listing, pages 1 through 14.
7. A Copy of The Sequence Listing in Computer Readable Form.
8. Statement Under 37 C.F.R. § 1.821(f) and (g).

9. Statutory Basic Filing Fee of \$395.00
10. Late Filing Fee Surcharge of \$65.00
11. Additional Claim Fee of \$256.00 (4 extra claims and 5 independent claims)
12. Return Receipt Postcard.

Please charge Deposit Account No. 502624 in the amount of \$716.00. To the extent necessary, Applicants petition for an extension of time under 37 C.F.R. 1.136. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.


Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:cec
Facsimile: 858.597.1585
Date: October 8, 2004



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILED OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/782,375	02/18/2004	Stefan M. Pulst	66783-145

CONFIRMATION NO. 3578

FORMALITIES LETTER



OC000000013528145

Cathryn Campbell
 McDERMOTT, WILL & EMERY
 7th Floor
 4370 La Jolla Village Drive
 San Diego, CA 92122

Date Mailed: 08/13/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 770 to complete the basic filing fee for a non-small entity. If appropriate, applicant may make a written assertion of entitlement to small entity status and pay the small entity filing fee (37 CFR 1.27).
- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- **For Rules Interpretation, call (703) 308-4216**
- **To Purchase PatentIn Software, call (703) 306-2600**
- **For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov**

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Additional claim fees of **\$502** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is **\$1402** for a Large Entity

- **\$770** Statutory basic filing fee.
- **\$130** Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is **\$502**
 - **\$430** for 5 independent claims over 3.
 - **\$72** for 4 total claims over 20.


Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



DECLARATION FOR PATENT APPLICATION

As the below-named inventors, we hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE, the specification of which

_____ is attached hereto as Attorney Client-Matter No. _____).

X was filed on February 18, 2004, as Application Serial No. 10/782,375. (Attorney Client-Matter No. 66783-145)

and was amended on (or amended through) _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to myself to be material to patentability as defined in Title 37, Code of Federal Regulations, Sec. 1.56.

Under Sec. 1.56, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) It refutes, or is inconsistent with, a position the applicant takes in: (a) Opposing an argument of unpatentability relied on by the U.S. Patent and Trademark Office, or (b) Asserting an argument of patentability.

I hereby claim the benefit under Title 35, United States Code, § 119(e) of the United States provisional application(s) listed below and claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject

Inventors: Pulst and Huynh

Serial No.: 10/782,375


Filed: February 18, 2004

Page 2

matter of each of the claims of these application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
60/448,252	February 18, 2003	Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Full name of first inventor:	Stefan M. Pulst
Inventor's signature:	
Date:	8/19/04
Residence:	Los Angeles, California 90046
Citizenship:	Germany
Mailing Address:	8125 Skyline Drive Los Angeles, California 90046

Inventors: Pulst and Huynh

Serial No.: 10/782,375

Filed: February 18, 2004

Page 3

Full name of second inventor:	Duong P. Huynh
Inventor's signature:	
Date:	3-21-04
Residence:	Long Beach, California
Citizenship:	United States of America
Mailing Address:	5953 Linden Avenue Long Beach, California 90805

POWER OF ATTORNEY FOR PATENT APPLICATION BY ASSIGNEE

Assignee Cedars-Sinai Medical Center is the owner of the entire right, title and interest of U.S. Patent Application Serial No. 10/782,375, filed on February 18, 2004, as attorney docket number 66783-145, and entitled PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE and any subsequently filed divisional, continuation, or reissue application, including international and foreign applications claiming priority thereto.

The Assignee hereby appoints the following attorneys to prosecute these applications and to transact all related business in the United States Patent and Trademark Office and any international and foreign patent offices:


CATHRYN CAMPBELL, Registration No. 31,815; **DAVID A. GAY**, Registration No. 39,200; **ANDREA L. GASHLER**, Registration No. 41,029; **DEBORAH L. CADENA**, Registration No. 44,048; **ASTRID R. SPAIN**, Registration No. 47,956; and **PAMELA M. GUY**, Registration No. 51,228.

Please direct all telephone calls to Cathryn Campbell at (858) 535-9001 and address all correspondence to:

CATHRYN CAMPBELL
McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

The undersigned is authorized to sign on behalf of the Assignee.

Signature:



Name (typed):

Peter E. Braverman

Title:

Senior Vice President for Legal Affairs
and General Counsel

Assignee:

CEDARS-SINAI MEDICAL CENTER

Date:

8/17/04

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Title of Application: **PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE**

Application Ser. No.: **10/782,375**

Filed: **February 18, 2004**

Inventor(s): **Pulst and Huynh**

Attorney Client-Matter No.: **66783-145**

CEDARS-SINAI MEDICAL CENTER, a non-profit organization, states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors of the application. A copy of the executed assignment, submitted for recording, is attached hereto as documentary evidence of the chain of title to the assignee.

The undersigned is empowered to sign this statement on behalf of the assignee.

8/17/04
Date

Name:



**Peter E. Braverman
Senior Vice President for Legal Affairs and
General Counsel**

Title:

**CEDARS-SINAI MEDICAL CENTER
8700 Beverly Boulevard
Los Angeles, California 90048-1865**

ASSIGNMENT

This Assignment is made by Stefan M. Pulst of Los Angeles, California and Duong P. Huynh of Long Beach, California, Assignors, to CEDARS-SINAI MEDICAL CENTER, Assignee, having a place of business at 8700 Beverly Boulevard, TSB 290 Los Angeles, California 90048

WHEREAS, Assignors have invented a new and useful PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE, for which an application for United States Letters Patent was filed on February 18, 2004, in the United States Patent and Trademark Office, bearing Serial No. 10/782,375 and identified as Attorney Client-Matter No: 66783-145;

WHEREAS, Assignors believe themselves to be the original inventors of the invention disclosed and claimed in said application for Letters Patent; and

WHEREAS, the parties desire to have a recordable instrument assigning an undivided part interest of Assignor's right, title and interest in and to said invention, said application and any Letters Patent that may be granted for said invention in the United States and throughout the world;

NOW, THEREFORE, in accordance with the obligations to assign the invention and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors sell, assign, and transfer to Assignee, an undivided part interest of Assignor's right, title, and interest in and to said invention, said application, any applications entitled to benefit of priority to said application under Title 35, United States Code, Sections 120, 121 or 251, which include divisionals, continuations and reissues, and any Letters Patent that may be granted on said invention or these applications in the United States and throughout the world, including the right to file foreign applications directly in the name of the Assignee and to

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 2 of 8

claim for any such foreign applications any priority rights to which such applications are entitled under international conventions, treaties, or otherwise.

Assignors agree that, upon request and without further compensation, but at no expense to Assignors, they and their legal representatives and assigns will do all lawful acts, including the execution of papers and the giving of testimony, that may be necessary or desirable for obtaining, sustaining, reissuing, or enforcing Letters Patent in the United States and throughout the world for said invention, and for perfecting, recording, or maintaining the title of Assignee, its successors and assigns, to said invention, said application, and any Letters Patent granted for said invention in the United States and throughout the world.

Assignors represent and warrant that they have not granted and will not grant to others any rights inconsistent with the rights as stated herein.

Assignors authorize and request that any United States or foreign Letters Patent granted for said invention, whether on said application or on any subsequently filed divisional, continuation or reissue application, be issued to Assignee, its successors and assigns, as the assignee of an undivided part interest of Assignor's interest in said invention.

Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004
Page 3 of 8

IN WITNESS WHEREOF, Assignors have executed this Assignment on the date(s) provided below.

Assignor: Stefan M. Pulst

Signature: Pulst

Date: 6-24-04


STATE OF California)

COUNTY OF Los Angeles)

On June 24, 2004, before me, June-Ellen Miller personally appeared Stefan M. Pulst, X personally known to me - OR proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS by hand and official seal.

June-Ellen Miller
(Signature of Notary)



Inventors: Pulst and Huynh
Serial No.: 10/782,375
Filed: February 18, 2004

Assignor: Duong P. Huynh

Signature:


Date:

STATE OF California)
COUNTY OF Los Angeles)

On 3/29/04, before me, JUNE-ELLEN MILLER personally appeared
Duong P. Huynh, ~~personally known to me - OR -~~ proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that ~~he/she/they~~ executed the same in ~~his/her/their~~ authorized capacity~~(ies)~~; and that by ~~his/her/their~~ signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS by hand and official seal.

(Signature of Notary)



PATENT
Client-Matter No.: 66783-145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Pulst and Huynh)
Serial No: 10/782,375)
Filed: February 18, 2004)
For: PARKIN INTERACTING)
POLYPEPTIDES AND METHODS)
OF USE)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SMALL ENTITY STATEMENT

The U.S. Patent and Trademark (USPTO) permits parties that establish status as a Small Entity to pay certain reduced fees (all citations to 37 C.F.R. § 1.27 except as noted). To be entitled to Small Entity Status, a party must be at least one of the following:

(1) Individual person:

An individual person, including an inventor and persons to whom an inventor has transferred some rights in the invention. § 1.27(a)(1).

(2) Small business concern:

A business concern whose number of employees, including affiliates, does not exceed 500 persons. § 1.27(a)(2) (incorporating 13 C.F.R. § 121.802).

“Business concern” means individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative. If the concern is a joint venture, participation by foreign business entities may not be more than 49%. 13 C.F.R. § 121.105.

The “number of employees” is the average number of employees, including the employees of its domestic and foreign affiliates, based on

Inventors: Pulst and Huynh

Serial No.: 10/782,375

Filed: February 18, 2004

Page 2

'numbers of employees for each of the pay periods for the preceding completed 12 calendar months. "Employees" includes all individuals employed on a full-time, part-time, temporary, or other basis. Part-time and temporary employees are counted the same as full-time employees. If a concern has not been in business for 12 months, use the average number of employees for each of the pay periods it has been in business. 13 C.F.R. § 121.106.

Concerns are "affiliates" of each other when one concern directly or indirectly controls or has the power to control the other, or when a third party or parties controls or has the power to control both concerns. 13 C.F.R. § 121.103(a).

(3) Nonprofit organization:

A university or other institution of higher education located in any country. § 1.27(a)(3) (ii)(A).

An organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1986 and exempt from taxation under section 501(a). Also included are such organizations located in a foreign country that would qualify if it were located in this country. § 1.27(a)(3)(ii)(B),(D).

A nonprofit scientific or educational organization qualified under a nonprofit organization statute of a U.S. state. Also included are such organizations located in a foreign country that would qualify if it were located in this country. § 1.27(a)(3)(ii)(C),(D).

Please note that a license to the Government resulting from a rights determination under Executive Order 10096 does not constitute a license that would prohibit claiming Small Entity Status. Similarly, for small business concerns and nonprofit organizations, a license to a Federal agency resulting from a funding agreement with that agency under 35 U.S.C. § 202(c)(4) is not a license that would prohibit claiming Small Entity Status. § 1.27(a)(4).

I hereby assert that I am empowered to sign on behalf of the party identified below ("Party"). Persons empowered to sign include, but are not limited to, an inventor him- or herself or an authorized officer of an assignee or licensee. See § 1.27(c)(2).

I have made a determination of the Party's entitlement to Small Entity Status, including a determination that all parties holding rights in the invention qualify for Small Entity Status. § 1.27(f).

Inventors: Pulst and Huynh

Serial No.: 10/782,375

Filed: February 18, 2004

Page 3

I hereby assert that the Party has not assigned, granted, conveyed or licensed--and is under no obligation under contract or law to do so--any rights in the invention to any other party that would not qualify as a Small Entity. Separate assertions of Small Entity Status should be obtained from each party having rights to the invention.

I hereby assert that the Party is entitled to be accorded Small Entity Status by the USPTO for the application or patent identified above. § 1.27(c)(1).

I understand that Small Entity Status must be newly determined when the issue fee and each maintenance fee is due. If there is any change resulting in loss of entitlement to Small Entity Status, I acknowledge the duty to file a notification to the USPTO in this application or patent before or upon paying the fee. § 1.27(g).

I understand that Small Entity Status must be separately established in any related application, including continuation, divisional, continuation-in-part, continued prosecution application or reissue application. § 1.27(c)(4).

I understand that any attempt to establish Small Entity Status improperly, deceptively or fraudulently will be considered a fraud practiced on the USPTO and may result in abandonment of the application or jeopardize the validity and enforceability of any resulting patent. § 1.27(h).

8/19/04
Date

Name:



Peter E. Braverman
Senior Vice President for Legal Affairs
and General Counsel

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Boulevard
Los Angeles, California 90048-1865

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Pulst, Stefan M., et al.

Customer No.: 41552

Appl. No. : 10/782,375

Confirmation No.: 3578

Filed : February 18, 2004

Title : PARKIN INTERACTING
POLYPEPTIDES AND METHODS
OF USE

Grp./A.U. : Unassigned


"Express Mail" Mailing Label Number EV 540 267 677 US

Examiner: : Unassigned

CERTIFICATE OF MAILING BY EXPRESS MAIL(37 CFR § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Oct. 8, 2004.


Debbie Cadena

STATEMENT UNDER 37 C.F.R. § 1.821(f) and (g)

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) herein does not include new matter.

Respectfully submitted,
MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena
Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:cec
Facsimile: 858.597.1585
Date: October 8, 2004

SEQUENCE LISTING

<110> Pulst, Stefan M.
Huynh, Duong P.

<120> Parkin Interacting Polypeptides and Methods of Use

<130> 66783-145

<140> US 10/782,375

<141> 2004-12-18

<150> 60/448,252

<151> 2003-02-18

<160> 15

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1453

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (272) . . . (955)

<221> misc feature

<222> (1) . . . (1453)

<223> n = A, T, C or G

<400> 1

ccg gga gta aag gcc ctc gtc tat gtc tgc ttc act gcc gtt ctt ggc 340
Pro Gly Val Lys Ala Leu Val Tyr Val Cys Phe Thr Ala Val Leu Gly
10 15 20

cat.tcc gtt ggt tgg cac cga ggg cac ttc gga caa cac gga ctg ggc 388
His Ser Val Gly Trp His Arg Gly His Phe Gly Gln His Gly Leu Gly
25 30 35

agg gga gca gtt aga acc cgg ctt tgg atc agg ccc gga cac gcg acg 436
Arg Gly Ala Val Arg Thr Arg Leu Trp Ile Arg Pro Gly His Ala Thr

40	45	50	55	
ttt ctt gga cag cg ^g cga gct gga cat caa tgc cg ^g ttc ccc gg ^g tcg Phe Leu Gly Gln Arg Arg Ala Gly His Gln Cys Arg Phe Pro Gly Ser				484
60	65		70	
cg ^c cg ^c cg ^c caa ctc ctc aag gag cc ^g aag cca agc cc ^g gcc gca ccc Arg Arg Arg Gln Leu Leu Lys Glu Pro Lys Pro Ser Pro Ala Ala Pro				532
75	80		85	
tcc tcc ttc tcc tcc cc ^g cc ^g cct gg ^g cc ^g cct aga atc gcc gct Ser Ser Phe Ser Ser Pro Pro Pro Gly Pro Pro Arg Ile Ala Ala				580
90	95		100	
gcc gcc ttc tcc tcc ccc gg ^c cgt tgt ggt tgt ggt tgt ccc tgc cac Ala Ala Phe Ser Ser Pro Gly Arg Cys Gly Cys Gly Cys Pro Cys His				628
105	110		115	
ctc ctt aca gcc gag cc ^g cc ^g aca caa gat gg ^c gga cg ^c ttg agc ctg Leu Leu Thr Ala Glu Pro Pro Thr Gln Asp Gly Arg Leu Ser Leu				676
120	125		130	
135				
gg ^g cc ^g gaa caa aac ctt gg ^g ccc cac cc ^g cag aaa cc ^g gga tgc aag Gly Pro Glu Gln Asn Leu Gly Pro His Pro Gln Lys Pro Gly Cys Lys				724
140	145		150	
cg ^g gcc gc ^g cct act tat gaa tca tgc ata aag ttc cct act cc ^g ttg Arg Ala Ala Pro Thr Tyr Glu Ser Cys Ile Lys Phe Pro Thr Arg Leu				772
155	160		165	
cga ttc att cg ^g tta gaa gt ^g gaa cag cac cc ^g ctg gt ^g gac att gt ^g Arg Phe Ile Arg Leu Glu Val Glu Gln His His Leu Val Asp Ile Val				820
170	175		180	
gca gta aca acg aaa aca ggt aaa aca gag gg ^c ac ^g cct cat gga at ^g Ala Val Thr Thr Lys Thr Gly Lys Thr Glu Ala Thr Pro His Gly Met				868
185	190		195	
cga cta at ^g aat gaa tt ^g tt ^g cag cca gg ^c t ^g taa gga agc gaa gaa Arg Leu Met Asn Glu Leu Leu Gln Pro Gly Cys Gln Gly Ser Glu Glu				916
200	205		210	
215				
aaa cc ^g tta agg cca tgc ttc ctg att ata agt tat gca tgaaggtag Lys Pro Leu Arg Pro Cys Phe Leu Ile Ile Ser Tyr Ala				965
220	225			
tggttggtag caacaaccag caaccagaaa gcagatgtta aaacatggaa gccacacacc cccattcatg aatnaatgtat gatcttgcag ggccccggaa gccaggaga cccaggccac				1025
aacttacttc atgaataatg catgaggccc agtgggttgg aataaaagg gcacgcccgc				1085
ctattgctgc atctaataca ctgtaagcag ggaaatgggg ctgctgcagg gaaaacacac				1145
tctcccggt cctgaataat gaattatgct gctgcagttag ctcaacctgg aaactcagag				1205
aggtaagaa aggttccacc caatttatga attatgcata aggccaagaa acacccaaga				1265
ctgcccctgcc cctcatttac ataaatatta tactagcatt taccatctca cttcttagaa				1325
				1385

tactagtata tcgctcacac ctcatatacct ccctactatg cctagaagga ataatactat 1445
cgctgtcg 1453

<210> 2

<211> 228

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Gln His Ile Gln Leu Pro Gly Val Lys Ala Leu Val Tyr Val
1 5 10 15
Cys Phe Thr Ala Val Leu Gly His Ser Val Gly Trp His Arg Gly His
20 25 30
Phe Gly Gln His Gly Leu Gly Arg Gly Ala Val Arg Thr Arg Leu Trp
35 40 45
Ile Arg Pro Gly His Ala Thr Phe Leu Gly Gln Arg Arg Ala Gly His
50 55 60
Gln Cys Arg Phe Pro Gly Ser Arg Arg Arg Gln Leu Leu Lys Glu Pro
65 70 75 80
Lys Pro Ser Pro Ala Ala Pro Ser Ser Phe Ser Ser Ser Pro Pro Pro
85 90 95
Gly Pro Pro Arg Ile Ala Ala Ala Ala Phe Ser Ser Pro Gly Arg Cys
100 105 110
Gly Cys Gly Cys Pro Cys His Leu Leu Thr Ala Glu Pro Pro Thr Gln
115 120 125
Asp Gly Gly Arg Leu Ser Leu Gly Pro Glu Gln Asn Leu Gly Pro His
130 135 140
Pro Gln Lys Pro Gly Cys Lys Arg Ala Ala Pro Thr Tyr Glu Ser Cys
145 150 155 160
Ile Lys Phe Pro Thr Arg Leu Arg Phe Ile Arg Leu Glu Val Glu Gln
165 170 175
His His Leu Val Asp Ile Val Ala Val Thr Thr Lys Thr Gly Lys Thr
180 185 190
Glu Ala Thr Pro His Gly Met Arg Leu Met Asn Glu Leu Leu Gln Pro
195 200 205
Gly Cys Gln Gly Ser Glu Glu Lys Pro Leu Arg Pro Cys Phe Leu Ile
210 215 220
Ile Ser Tyr Ala
225

<210> 3

<211> 684

<212> DNA

<213> Homo sapiens

<400> 3

atggcccaac acatacagct gccggagta aaggccctcg tctatgtctg cttaactgcc 60.
gttcttggcc attccgttgg ttggcaccga gggacttcg gacaacacgg actggcagg 120
ggagcagtta gaacccggct ttggatcagg cccggacacg cgacgtttct tggacagcgg 180
cgagctggac atcaatgccg gttccccggg tcgcggccgc gccaactcct caaggagccg 240
aagccaagcc cggccgcacc ctcccttc tcctcctccc cgccgcctgg gccgcctaga 300
atcgccgctg ccgccttctc ctccccggc cggttgtgtcc gtgggtgtcc ctgccacctc 360
cttacagccg agccgcccac acaagatggc ggacgcttga gcctggggcc ggaacaaaac 420

cttgggcccc acccccagaa acccgatgc aagcggccg cgcctactta tgaatcatgc	480
ataaaagtcc ctactcggtt gcgattcatt cggttagaag tggaacagca ccacctggtg	540
gacattgtgg cagtaacaac gaaaacaggt aaaacagagg ccacgcctca tggaatgcga	600
ctaataaatg aattgttgca gccaggctgt caaggaagcg aagaaaaacc gttaaggcca	660
tgcttcctga ttataagttt tgca	684

<210> 4
<211> 958
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1) ... (958)
<223> n = A,T,C or G

<400> 4

gaattcgcgg cgcgtcgac ctccttctcc tcctccccgc cgctgngcc gcctagaatc	60
gccgctgccg ccttctcctc ccccgccgt tgtggttgtg gttgtccctg ccacctcctt	120
acagccgagc cgccgacaca agatggcgga cgctgagcct gggccggaa caaaaccttg	180
ggccccaccc ccagaaaccc ggatgcaagc gggccgcgc tacttatgaa tcatgcataa	240
agttccctac tcgggttgcga ttcattcggt tagaagtggaa acagcaccac ctggtgacca	300
tttgtggcagt aacaacgaaa acaggtnaaa cagaagccac gcctcatgga atgctgactaa	360
tgaatgaatt gttgcagcca ggctgtcaag gaagcgaaaa aaaaaccgtt aaggccatgc	420
ttcctgatta taagttatgc atgaagttga gtgggttggta gacttaacaa ccagcaacca	480
gaaagcagat gttaaaacat ggaagccaca cacccccatt catgaataat gatgatcttg	540
cagggggcccg gaagccaagg agaccaggc cacaacttac ttcattgata atgcattgagg	600
cccagtgggt tggataaaaa gggcacgccc cgccattgc tgcatctaat acactgtaa	660
cagggaaatg gggctgctgc agggaaaaaca cactctccca ggtcctgaat aatgaattat	720
gctgctgcag tagctcaacc tggaaactca gagaggtcaa gaaaggttcc acccaattta	780
tgaattatgc ataaggcgaa gaaacaccca agactgccct gcccctcatt tacataaata	840
ttatacttagc atttaccatc tcacttcttag gaataactagt atatcgctca cacctcatat	900
cctccctact atgccttagaa ggaataatac tatcgctgtc gacgcggcc gcgaattc	958

<210> 5
<211> 2453
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (266) ... (1534)

<400> 5

agagcactgg ggaccgagac cggcaccac ctcccggtcc gccctccagg gaaaacggga	60
aaactagcaa gagctagcaa gaactagcaa gagcttgaac aaacgcctgg actcagattg	120
gaagactgct catttgcata ctgcctcatt cctggaaatt gcactggaaac tgtctgatta	180
agaaaaacag aataattctg aaagaaagaa aacaaagaaa aacatactcc agaattccta	240
atagaacact tcacctgaac ctaaa atg gtg agc gag agt cac cat gag gcc	292
Met Val Ser Glu Ser His His Glu Ala	
1	5

ctg gca gcc ccg cct gtc acc act gtc gcg act gtt ctg cca agc aat 340

Leu Ala Ala Pro Pro Val Thr Thr Val Ala Thr Val Leu Pro Ser Asn				
10	15	20	25	
gcc aca gag cca gcc agt cct gga gaa gga aag gaa gat gca ttt tct				388
Ala Thr Glu Pro Ala Ser Pro Gly Glu Gly Lys Glu Asp Ala Phe Ser				
30	35	40		
aag ctg aag gag aag ttt atg aat gag ttg cat aaa att cca ttg cca				436
Lys Leu Lys Glu Lys Phe Met Asn Glu Leu His Lys Ile Pro Leu Pro				
45	50	55		
ccg tgg gcc tta att gca ata gcc ata gtc gca gtc ctt tta gtc ctg				484
Pro Trp Ala Leu Ile Ala Ile Ala Ile Val Ala Val Leu Leu Val Leu				
60	65	70		
acc tgc tgc ttt tgt atc tgt aag aaa tgt ttg ttc aaa aag aaa aac				532
Thr Cys Cys Phe Cys Ile Cys Lys Lys Cys Leu Phe Lys Lys Lys Asn				
75	80	85		
aag aag aag gga aag gaa aaa gga ggg aag aat gcc att aac atg aaa				580
Lys Lys Lys Gly Lys Glu Lys Gly Lys Asn Ala Ile Asn Met Lys				
90	95	100	105	
gat gta aaa gac tta ggg aag acg atg aaa gat cag gcc ctc aag gat				628
Asp Val Lys Asp Leu Gly Lys Thr Met Lys Asp Gln Ala Leu Lys Asp				
110	115	120		
gat gat gct gaa act gga ttg aca gat gga gaa gaa aaa gaa gaa ccc				676
Asp Asp Ala Glu Thr Gly Leu Thr Asp Gly Glu Glu Lys Glu Glu Pro				
125	130	135		
aaa gaa gag gag aaa ctg gga aaa ctt cag tat tca ctg gat tat gat				724
Lys Glu Glu Lys Leu Gly Lys Leu Gln Tyr Ser Leu Asp Tyr Asp				
140	145	150		
ttc caa aat aac cag ctg ctg gta ggg atc att cag gct gcc gaa ctg				772
Phe Gln Asn Asn Gln Leu Leu Val Gly Ile Ile Gln Ala Ala Glu Leu				
155	160	165		
ccc gcc ttg gac atg ggg ggc aca tct gat cct tac gtg aaa gtg ttt				820
Pro Ala Leu Asp Met Gly Gly Thr Ser Asp Pro Tyr Val Lys Val Phe				
170	175	180	185	
ctg cta cct gat aag aag aaa ttt gag aca aaa gtc cac cga aaa				868
Leu Leu Pro Asp Lys Lys Lys Phe Glu Thr Lys Val His Arg Lys				
190	195	200		
acc ctt aat cct gtc ttc aat gag caa ttt act ttc aag gta cca tac				916
Thr Leu Asn Pro Val Phe Asn Glu Gln Phe Thr Phe Lys Val Pro Tyr				
205	210	215		
tcg gaa ttg ggt ggc aaa acc cta gtg atg gct gta tat gat ttt gat				964
Ser Glu Leu Gly Gly Lys Thr Leu Val Met Ala Val Tyr Asp Phe Asp				

220	225	230	
cgt ttc tct aag cat gac atc att gga gaa ttt aaa gtc cct atg aac Arg Phe Ser Lys His Asp Ile Ile Gly Glu Phe Lys Val Pro Met Asn 235	240	245	1012
aca gtg gat ttt ggc cat gta act gag gaa tgg cgt gac ctg caa agt Thr Val Asp Phe Gly His Val Thr Glu Glu Trp Arg Asp Leu Gln Ser 250	255	260	1060
gct gag aag gaa gag caa gag aaa ttg ggt gat atc tgc ttc tcc ctt Ala Glu Lys Glu Glu Gln Lys Leu Gly Asp Ile Cys Phe Ser Leu 270	275	280	1108
cgc tac gta cct act gct ggt aag ctg act gtt gtc att ctg gag gca Arg Tyr Val Pro Thr Ala Gly Lys Leu Thr Val Val Ile Leu Glu Ala 285	290	295	1156
aag aac ctg aag aag atg gat gtg ggt ggc tta tcc gat cct tat gtg Lys Asn Leu Lys Lys Met Asp Val Gly Gly Leu Ser Asp Pro Tyr Val 300	305	310	1204
aag att cat ctg atg cag aat ggt aag agg ctg aag aag aaa aag aca Lys Ile His Leu Met Gln Asn Gly Lys Arg Leu Lys Lys Lys Thr 315	320	325	1252
aca att aaa aag aac aca ctt aac ccc tac tac aat gag tca ttc agc Thr Ile Lys Lys Asn Thr Leu Asn Pro Tyr Tyr Asn Glu Ser Phe Ser 330	335	340	1300
ttt gaa gta cct ttt gaa caa atc cag aaa gtg cag gtg gtg gta act Phe Glu Val Pro Phe Glu Gln Ile Gln Lys Val Gln Val Val Val Thr 350	355	360	1348
gtt ttg gac tat gac aag att ggc aag aac gat gcc atc ggc aaa gtc Val Leu Asp Tyr Asp Lys Ile Gly Lys Asn Asp Ala Ile Gly Lys Val 365	370	375	1396
ttt gtg ggc tac aac agc acc ggc gcg gag ctg cga cac tgg tca gac Phe Val Gly Tyr Asn Ser Thr Gly Ala Glu Leu Arg His Trp Ser Asp 380	385	390	1444
atg ctg gcc aac ccc agg cga cct att gcc cag tgg cac acc ctg cag Met Leu Ala Asn Pro Arg Arg Pro Ile Ala Gln Trp His Thr Leu Gln 395	400	405	1492
gta gag gag gaa gtt gat gcc atg ctg gcc gtc aag aag taa Val Glu Glu Val Asp Ala Met Leu Ala Val Lys Lys *410	415	420	1534
aggaaaagaag aagcctttct gcatttgccc atatagtgct cttagccag tatctgtaaa tacctcagta atatgggtcc tttcattttt ccagccatgc attcctaaca caattcagtg gtacttgaa tcctgtttta atttgaccaa atttaaatgt agagagcccc taagtcccttc			1594
			1654
			1714

atcataccac tgccctccaa atctactctt ctttaagca atatgatgtg tagatagagc	1774
atgaatgaaa ttatttattg tatcacactg ttgtatatac cagtatgcta aagatttatt	1834
tctagttgt gtatttgtat gttgtaagcg tttcctaatac tgttatatac tagatgttt	1894
taataagatg ttctattta aactatgtaa attgactgag atataggaga gctgataata	1954
tattatacgg taaatatagt atcgcttgca ttccagcaaa aatatcaact cgtaaggcac	2014
tagtacagtt aaactgacat cttaaaggac aacttaaacc tgagcttctt attgaatcat	2074
ttgagtagcca agataaaactt acaccacata cttgggggt gaatccaatt ttgtagaatt	2134
cctacacagg caaaaatagca tgatctgagc agcagcatcc aggctgacct caaggaagca	2194
tagccacaaa acagaatagc acctgtctgt acatatttac aaagctaaaa taatggcttc	2254
actcttatat ttgaggaagc aactgaacag gagtcaatga tttcatatta ctgcataata	2314
aataacaaca aggtgttccg tgtgtgtgtg tgtgtgtgtg cacattgtt	2374
tggggatggg ggagaagaag ctaagggag aagtcaacat ttatgaaata ttgcctgact	2434
attnnnnnnnn nnnnnnnnnn	2453

<210> 6

<211> 422

<212> PRT

<213> Homo sapiens

<400> 6

Met Val Ser Glu Ser His His Glu Ala Leu Ala Ala Pro Pro Val Thr	
1 5 10 15	
Thr Val Ala Thr Val Leu Pro Ser Asn Ala Thr Glu Pro Ala Ser Pro	
20 25 30	
Gly Glu Gly Lys Glu Asp Ala Phe Ser Lys Leu Lys Glu Lys Phe Met	
35 40 45	
Asn Glu Leu His Lys Ile Pro Leu Pro Pro Trp Ala Leu Ile Ala Ile	
50 55 60	
Ala Ile Val Ala Val Leu Leu Val Leu Thr Cys Cys Phe Cys Ile Cys	
65 70 75 80	
Lys Lys Cys Leu Phe Lys Lys Lys Asn Lys Lys Lys Gly Lys Glu Lys	
85 90 95	
Gly Gly Lys Asn Ala Ile Asn Met Lys Asp Val Lys Asp Leu Gly Lys	
100 105 110	
Thr Met Lys Asp Gln Ala Leu Lys Asp Asp Asp Ala Glu Thr Gly Leu	
115 120 125	
Thr Asp Gly Glu Glu Lys Glu Glu Pro Lys Glu Glu Lys Leu Gly	
130 135 140	
Lys Leu Gln Tyr Ser Leu Asp Tyr Asp Phe Gln Asn Asn Gln Leu Leu	
145 150 155 160	
Val Gly Ile Ile Gln Ala Ala Glu Leu Pro Ala Leu Asp Met Gly Gly	
165 170 175	
Thr Ser Asp Pro Tyr Val Lys Val Phe Leu Leu Pro Asp Lys Lys Lys	
180 185 190	
Lys Phe Glu Thr Lys Val His Arg Lys Thr Leu Asn Pro Val Phe Asn	
195 200 205	
Glu Gln Phe Thr Phe Lys Val Pro Tyr Ser Glu Leu Gly Gly Lys Thr	
210 215 220	
Leu Val Met Ala Val Tyr Asp Phe Asp Arg Phe Ser Lys His Asp Ile	
225 230 235 240	
Ile Gly Glu Phe Lys Val Pro Met Asn Thr Val Asp Phe Gly His Val	
245 250 255	
Thr Glu Glu Trp Arg Asp Leu Gln Ser Ala Glu Lys Glu Gln Glu	

260	265	270
Lys Leu Gly Asp Ile Cys Phe Ser	Leu Arg Tyr Val Pro Thr Ala Gly	
275	280	285
Lys Leu Thr Val Val Ile Leu Glu Ala Lys Asn Leu Lys Lys Met Asp		
290	295	300
Val Gly Gly Leu Ser Asp Pro Tyr Val Lys Ile His Leu Met Gln Asn		
305	310	315
Gly Lys Arg Leu Lys Lys Lys Thr Thr Ile Lys Lys Asn Thr Leu		
325	330	335
Asn Pro Tyr Tyr Asn Glu Ser Phe Ser Phe Glu Val Pro Phe Glu Gln		
340	345	350
Ile Gln Lys Val Gln Val Val Val Thr Val Leu Asp Tyr Asp Lys Ile		
355	360	365
Gly Lys Asn Asp Ala Ile Gly Lys Val Phe Val Gly Tyr Asn Ser Thr		
370	375	380
Gly Ala Glu Leu Arg His Trp Ser Asp Met Leu Ala Asn Pro Arg Arg		
385	390	395
Pro Ile Ala Gln Trp His Thr Leu Gln Val Glu Glu Glu Val Asp Ala		
405	410	415
Met Leu Ala Val Lys Lys		
420		

<210> 7

<211> 5103

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (254) ... (1549)

<400> 7

agaaggcgga gcctacctct catcaggacc agtctgactg cacctgcatt ctttagctcag	60	
agcatccccg gagcatctta agagctgagc gcagctgaca actaggggcc ggaccgtcgc	120	
aggaggcgtc cgctggatac cttccccctt ccctgaccta gagctctaca gctgctgcct	180	
cggtaactgac cgagggttcc cagagctgtc tcaccattgc aaaaacgtta tagcaacagc	240	
ctctgattac gac atg gct gag atc acc aat atc cga cct agc ttt gat	289	
Met Ala Glu Ile Thr Asn Ile Arg Pro Ser Phe Asp		
1	5	10

gtg tca ccg gtg gtg gcc ggc ctc atc ggg gcc tct gtg ctg gtg gtg	337	
Val Ser Pro Val Val Ala Gly Leu Ile Gly Ala Ser Val Leu Val Val		
15	20	25

tgt gtc tcg gtg acc gtc ttt gtc tgg tca tgc tgc cac cag cag gca	385	
Cys Val Ser Val Thr Val Phe Val Trp Ser Cys Cys His Gln Gln Ala		
30	35	40

gag aag aag cac aag aac cca cca tac aag ttt att cac atg ctc aaa	433	
Glu Lys Lys His Lys Asn Pro Pro Tyr Lys Phe Ile His Met Leu Lys		
45	50	55
		60

ggc atc agc ata tac cca gag acc ctc agc aac aag aag aaa atc atc	481
---	-----

Gly Ile Ser Ile Tyr Pro Glu Thr Leu Ser Asn Lys Lys Lys Ile Ile
65 70 75

aaa gtg cgg aga gac aaa gat ggt cct ggg agg gaa ggt gga cgt agg 529
Lys Val Arg Arg Asp Lys Asp Gly Pro Gly Arg Glu Gly Gly Arg Arg
80 85 90

aac ctg ttg gtg gac gca gca gag gct ggc ctg cta agc cga gac aaa 577
Asn Leu Leu Val Asp Ala Ala Glu Ala Gly Leu Leu Ser Arg Asp Lys
95 100 105

gat ccc agg ggg cct agc tct gga tct tgt ata gac caa tta ccc atc 625
Asp Pro Arg Gly Pro Ser Ser Gly Ser Cys Ile Asp Gln Leu Pro Ile
110 115 120

aaa atg gac tat ggg gaa gaa cta agg agc cct att aca agc ctg acc 673
Lys Met Asp Tyr Gly Glu Glu Leu Arg Ser Pro Ile Thr Ser Leu Thr
125 130 135 140

cct ggg gag agc aaa acc acc tct cca tca tct cca gag gag gat gtc 721
Pro Gly Glu Ser Lys Thr Ser Pro Ser Ser Pro Glu Glu Asp Val
145 150 155

atg cta gga tcc ctc acc ttc tca gtg gac tat aac ttc ccg aaa aaa 769
Met Leu Gly Ser Leu Thr Phe Ser Val Asp Tyr Asn Phe Pro Lys Lys
160 165 170

gcc ctg gtg gtg aca atc cag gag gcc cac ggg ctg cca gtg atg gat 817
Ala Leu Val Val Thr Ile Gln Glu Ala His Gly Leu Pro Val Met Asp
175 180 185

gac cag acc cag gga tct gac ccc tac atc aaa atg acc atc ctt cct 865
Asp Gln Thr Gln Gly Ser Asp Pro Tyr Ile Lys Met Thr Ile Leu Pro
190 195 200

gac aaa cgg cat cgg gtg aag acc aga gtg ctg cgg aag acc ctg gac 913
Asp Lys Arg His Arg Val Lys Thr Arg Val Leu Arg Lys Thr Leu Asp
205 210 215 220

cct gtg ttt gac gag acc ttc acc ttc tat gtc atc ccc tac agc cag 961
Pro Val Phe Asp Glu Thr Phe Thr Tyr Val Ile Pro Tyr Ser Gln
225 230 235

ctg cag gac ctg gtg ctg cac ttc ctt gtc ctc agc ttt gac cgc ttc 1009
Leu Gln Asp Leu Val Leu His Phe Leu Val Leu Ser Phe Asp Arg Phe
240 245 250

tct cgg gat gat gtc att ggc gag gtc atg gtg cca ctg gca ggg gtg 1057
Ser Arg Asp Asp Val Ile Gly Glu Val Met Val Pro Leu Ala Gly Val
255 260 265

gac ccc agc aca ggc aag gta caa ctg acc agg gac atc atc aaa agg 1105
Asp Pro Ser Thr Gly Lys Val Gln Leu Thr Arg Asp Ile Ile Lys Arg

270	275	280	
atc cag aag tgc atc agc aga ggg gag ctc cag gtg tct ctg tca Ile Gln Lys Cys Ile Ser Arg Gly Glu Leu Gln Val Ser Ile Ser	290	295	300
cag cct gtg gca cag aga atg aca gtg gtg gtc ctc aaa gcc aga Gln Pro Val Ala Gln Arg Met Thr Val Val Val Leu Lys Ala Arg	305	310	315
ttg ccg aag atg gat atc acc ggt ctc tca ggt aat cct tat gtc Leu Pro Lys Met Asp Ile Thr Gly Leu Ser Gly Asn Pro Tyr Val	320	325	330
gtg aac gtc tac tac ggc aga aag cgc att gcc aag aag aaa acc Val Asn Val Tyr Tyr Gly Arg Lys Arg Ile Ala Lys Lys Lys Thr	335	340	345
gtg aag aag tgc act ttg aac ccc atc ttc aat gaa tct ttc atc Val Lys Lys Cys Thr Leu Asn Pro Ile Phe Asn Glu Ser Phe Ile	350	355	360
gac atc ccc act gac ctc ctg cct gat atc agc atc gag ttc ctc Asp Ile Pro Thr Asp Leu Leu Pro Asp Ile Ser Ile Glu Phe Leu	370	375	380
atc gac ttc gat cgc acc acc aag aat gag .gtg gtg ggg agg ctg Ile Asp Phe Asp Arg Thr Thr Lys Asn Glu Val Val Gly Arg Leu	385	390	395
ctg ggg gca cac agt gtc aca gcc agt ggt gct gaa cac tgg aga Leu Gly Ala His Ser Val Thr Ala Ser Gly Ala Glu His Trp Arg	400	405	410
gtc tgc gag agc ccc cgc aag cct gtg gcc aag tgg cac agt ctg Val Cys Glu Ser Pro Arg Lys Pro Val Ala Lys Trp His Ser Leu	415	420	425
gag tac taa tcctgttctt ctctcctcta atccccgggg gccaagctgg Glu Tyr *	430		1589
ggatgt ggagggaaa aagatgacag agaagtggac tccaaacctc atttagttg aaaaaaa tttcttacaa aacaaattcc acaaagaaca ccctatatga ccacagctgc cagttc ttagcaatga tgtttttt tctgcttgc aaggcgctag aatctttat ctttat ttttttgag gtggagttc gctctgttgc cccggctgg agtcaatgg atctca actcactgca acctctgccc ttcaggttca agtattctc ctccctcagc ccaagta gctgggatta caggcaccca cgagcatgcc cggctaattt tttgtatTTT agagat gggttcacc atgttggcca ggctggtctc gaattccaga cctcaggtga ccccgcc tcggcctccc aaagtgctgg gattacaggt gcgagccacc gtgcccggcc gttttg ttttgtttt ttttttaat gggggacaaa agagagggaa agacccctat ctatat ataacaatgt aaccatatac ttgcattgtct aatacactt gaaatgtt aactqc caatatcaaqtqcaqattt taatccatqq aaattgttqtt ttgtqctqaa	1649 1709 1769 1829 1889 1949 2009 2069 2129 2189 2249		

ttgtatggc tgattacctg aaattggctt ctttttattg ggcttctctg gagaatttct	2309
cccaactcccc acctctgcag aagaaaattt tgctcttata aaacacctatg ttttcatcat	2369
tcctatctt tcttttattt gcctcttata tctctgtct ttgacctcaa ggtcttagagg	2429
tctgcagtaa gccaaagaaac aaaggtgggg tggatgagga aaggtttgcg ggagaaagag	2489
gaattgagaa atgggttatt tttgctatca gctcttctgc tatgaagtag taaaaggcag	2549
tctataatta actgacagac ctaactgaag cacagagaat acatcagact tatgcatcca	2609
agacatcaga acttggattt tatcaaactt gatgacttct ctaaaaggag ctttgaaac	2669
ttcaaattca gctataggat agtaccaatg aacacatcca gctgatccc aaagctgtt	2729
tcaggtataa ggacaaggag aggagacaag tgacgacagc cattccctt tgcaagctatc	2789
tactgttagtg acagccattt cttgggtat gggttggaaag tcatacgagg tttgaagaat	2849
tacactggcc tttgttttc tggaaatgcc gaccatggag atgctttaga gtcttctaaa	2909
atagcttaga tggtaatg aggttagct tgcttcataa aacagggcc ctcagaagtt	2969
ctccttaaat tttcaataa aaatttagct cttaaaaaaa taacagtgtg actgagtgaa	3029
tgaagataag ttggatttt tcagagcatt ctttcctca aaacgagctg cataattctt	3089
ggaatttatg tcttaccaca tggtgaggg atggggaaac tacaggatgc aattcttctt	3149
ctaccaatgg gcaatagagg ttgagagaga ttcatcgatct ttctgggatt agaattcaag	3209
tctcttact cctacagcag ctgcgtctcc aacgttgaga ctggcagat ggcacagact	3269
ccatggataa tagttaact tggggccggg cgcatgtggct cacgcctgtt atcccggtat	3329
tttgggaggc cgagggtggaa agatcgctt agcccaggag ttcaagacca gcctggcta	3389
catgacaaaa ctccatctt atcaaaaata caaaaaattt actaggtgtg gtgctgcacg	3449
cctgtggtcc cagctattca ggaggctgag gtgggaggat cattgagcc cagaggtaga	3509
ggctgcagtg agccatgatc atgccactgc actctggct gggtaacaga gtgagatcct	3569
gtctcaaaaa ttaattaatt aattaattaa aataaactag gtaaaacttgg ataggcagta	3629
gatattttt cccacctgag gaggatctca gtcaagctgt tgcttaacag cttgatccag	3689
ggcgtgaaag gttagttgag actgaagtgt tcacttccat agaagaacat cacttttaac	3749
cttgctttgg cgaaggagt cgaaaagctg agtctctatg gacggggggg tgatcttgct	3809
ttcagtgttc cctcagctt tggattta aaaccattct gctcccccta aacctttgt	3869
ttgatttcag cccatgttct tgacaatgca gagcaattct gagcagtcac aaagcctact	3929
ctctgttctt gtccctgcca acccccaccc cccataatct gactcacaac ttcaccatca	3989
gttgggtca taccactgt ctctgtccta taccctatga aatgtaaata ctgtatcata	4049
agtagaaagaa aataattttt gtttctaaa aatgcatttt gagatagttt aatgtaaatc	4109
tgacaggagc attctgaagc cccatttaga aaaaatttaa atggccctc ttcatcgcc	4169
taatgtctaa agatcagaaa tcgctgagca aaccgcctt tgcccttc ccagaaacaa	4229
tgcaaaacaa caggtggaga tagtctggtc tttgcctgc tgtgtgtgcc tctgtagctc	4289
ctcctgacaa acgtctggc aaacagcctc accccactct cctctctt cccatttcc	4349
tttagctttt attccttgca tctttgggtc tactgagcag tgggtgtga ggtgacagg	4409
gaggaaccag ttgttctgtt gccttaggaac tgcctcagtg tctttgcag aaaaaggcaa	4469
agaggcggac agtgcagggc tcctccctcc tacctcagggc ctgatccatc gtcccttga	4529
ctttgccgtc tcaaagttt ttagctgact ttggcttca cattgttct ttccagagct	4589
aactgataag agtggaggag gaatgccttc tcctaagagt cagttgaaag aaagacaaga	4649
gagtcacatc ttagctttt cacaaggcat tcgtggcag gaataggtt gggaaatggtc	4709
acttctgatt ttccaacagt tgctccttct ctgaagagat cttgattcct ttggaaagac	4769
aagaattttt cttataaca aagtcactt tatgagttat tccttcttc agttcatctc	4829
actggagcac agccaagatg gacatgtta tggacagtgc tctagatgtg aaaacagata	4889
gaactggttt gtggacagg ggcagctgc tcaggagagg gaataacgca ggtcccttt	4949
cttggaggc ttgtactatg gccatgacag tgacattgcc ctcaccatga tccctctcca	5009
aagtgggtgt cttctttac cttgtgtctt ctcttgtaaa aatgaaactc aaaaataaaaa	5069
taaatgtgtc aaatttcgaa aaaaaaaaaa aaaa	5103

<210> 8
<211> 431
<212> PRT
<213> Homo sapiens

<400> 8

Met Ala Glu Ile Thr Asn Ile Arg Pro Ser Phe Asp Val Ser Pro Val
1 5 10 15
Val Ala Gly Leu Ile Gly Ala Ser Val Leu Val Val Cys Val Ser Val
20 25 30
Thr Val Phe Val Trp Ser Cys Cys His Gln Gln Ala Glu Lys Lys His
35 40 45
Lys Asn Pro Pro Tyr Lys Phe Ile His Met Leu Lys Gly Ile Ser Ile
50 55 60
Tyr Pro Glu Thr Leu Ser Asn Lys Lys Ile Ile Lys Val Arg Arg
65 70 75 80
Asp Lys Asp Gly Pro Gly Arg Glu Gly Gly Arg Arg Asn Leu Leu Val
85 90 95
Asp Ala Ala Glu Ala Gly Leu Leu Ser Arg Asp Lys Asp Pro Arg Gly
100 105 110
Pro Ser Ser Gly Ser Cys Ile Asp Gln Leu Pro Ile Lys Met Asp Tyr
115 120 125
Gly Glu Glu Leu Arg Ser Pro Ile Thr Ser Leu Thr Pro Gly Glu Ser
130 135 140
Lys Thr Thr Ser Pro Ser Pro Glu Glu Asp Val Met Leu Gly Ser
145 150 155 160
Leu Thr Phe Ser Val Asp Tyr Asn Phe Pro Lys Lys Ala Leu Val Val
165 170 175
Thr Ile Gln Glu Ala His Gly Leu Pro Val Met Asp Asp Gln Thr Gln
180 185 190
Gly Ser Asp Pro Tyr Ile Lys Met Thr Ile Leu Pro Asp Lys Arg His
195 200 205
Arg Val Lys Thr Arg Val Leu Arg Lys Thr Leu Asp Pro Val Phe Asp
210 215 220
Glu Thr Phe Thr Phe Tyr Val Ile Pro Tyr Ser Gln Leu Gln Asp Leu
225 230 235 240
Val Leu His Phe Leu Val Leu Ser Phe Asp Arg Phe Ser Arg Asp Asp
245 250 255
Val Ile Gly Glu Val Met Val Pro Leu Ala Gly Val Asp Pro Ser Thr
260 265 270
Gly Lys Val Gln Leu Thr Arg Asp Ile Ile Lys Arg Asn Ile Gln Lys
275 280 285
Cys Ile Ser Arg Gly Glu Leu Gln Val Ser Leu Ser Tyr Gln Pro Val
290 295 300
Ala Gln Arg Met Thr Val Val Leu Lys Ala Arg His Leu Pro Lys
305 310 315 320
Met Asp Ile Thr Gly Leu Ser Gly Asn Pro Tyr Val Lys Val Asn Val
325 330 335
Tyr Tyr Gly Arg Lys Arg Ile Ala Lys Lys Lys Thr His Val Lys Lys
340 345 350
Cys Thr Leu Asn Pro Ile Phe Asn Glu Ser Phe Ile Tyr Asp Ile Pro
355 360 365
Thr Asp Leu Leu Pro Asp Ile Ser Ile Glu Phe Leu Val Ile Asp Phe
370 375 380
Asp Arg Thr Thr Lys Asn Glu Val Val Gly Arg Leu Ile Leu Gly Ala
385 390 395 400
His Ser Val Thr Ala Ser Gly Ala Glu His Trp Arg Glu Val Cys Glu

405 410 415
Ser Pro Arg Lys Pro Val Ala Lys Trp His Ser Leu Ser Glu Tyr
420 425 430

<210> 9
<211> 15
<212> PRT
<213> Homo sapiens

<400> 9
His Gln Gln Ala Glu Lys Lys Gln Lys Asn Pro Pro Tyr Lys Phe
1 5 10 15

<210> 10
<211> 16
<212> PRT
<213> Homo sapiens

<400> 10
Lys Val Arg Arg Asp Lys Asp Gly Pro Arg Arg Glu Ser Gly Arg Gly
1 5 10 15

<210> 11
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> forward primer

<400> 11
Lys Val Arg Arg Asp Lys Asp Gly Pro Arg Arg Glu Ser Gly Arg Gly
1 5 10 15

<210> 12
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> reverse primer

<400> 12
Thr Thr Thr Cys Cys Thr Thr Ala Cys Thr Thr Cys Thr Thr Gly
1 5 10 15
Ala Cys Gly

<210> 13
<211> 21
<212> PRT
<213> Artificial Sequence

<220>

<223> reverse primer

<400> 13

Thr Gly Ala Ala Gly Gly Ala Cys Thr Thr Ala Gly Gly Gly Cys

1 5 10

15

Thr Cys Thr Cys Thr

20

<210> 14

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> forward primer

<400> 14

Gly Ala Gly Gly Gly Thr Thr Cys Cys Cys Ala Gly Ala Gly Cys Thr

1 5 10

15

Gly Thr Cys Thr

20

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 15

Cys Ala Cys Ala Thr Cys Cys Cys Thr Cys Cys Cys Cys Ala Gly Cys

1 5 10

15

Thr Thr Gly



EV 540267677 US

Mailing Label
 Label 11-F June 2002


UNITED STATES POSTAL SERVICE®

Post Office To Addressee

ORIGIN (POSTAL USE ONLY)		
PO ZIP Code	Day of Delivery	Flat Rate Envelope
	<input type="checkbox"/> Next <input type="checkbox"/> Second	<input type="checkbox"/>
Date In	Postage	
Mo. Day Year	<input type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	\$
Time In	Military	Return Receipt Fee
<input type="checkbox"/> AM <input type="checkbox"/> PM	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	
Weight	Int'l Alpha Country Code	COD Fee Insurance Fee
Ibs. ozs.		
No Delivery	Acceptance Clerk Initials	Total Postage & Fees
<input type="checkbox"/> Weekend <input type="checkbox"/> Holiday		\$

DELIVERY (POSTAL USE ONLY)		
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Attempt	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	
Delivery Date	Time	Employee Signature
Mo. Day	<input type="checkbox"/> AM <input type="checkbox"/> PM	

WAIVER OF SIGNATURE (Domestic Only) Additional merchandise insurance is void if delivery of signature is required. I wish delivery to be made without obtaining signature of addressee or addressee's agent. If delivery employee judges that addressee can be left in secure location) and authorize that delivery employee's signature constitutes valid proof of delivery.

NO DELIVERY Weekend Holiday Customer Signature

CUSTOMER USE ONLY

METHOD OF PAYMENT:
Express Mail Corporate Acct. No.

Federal Agency Acct. No. or
Postal Service Acct. No.

FROM: (PLEASE PRINT) **PHONE** 858 535 9001

MCDERMOTT WILL & EMERY LLP
4370 LA JOLLA VILLAGE DR STE 700
SAN DIEGO CA 92122-1252

PULST 066783-0145 (DCC/ccc) (7312)

TO: (PLEASE PRINT) **PHONE**

F MALL STOP MISSING PARTS
COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA VA 22313-1450

PRESS HARD.
You are making 3 copies. **FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com**



135 / 200 4:02 : 1 : 12

Applicant: **Pulst, Stefan M., et al.**Docket No. **066783-0145**Title: **PARKIN INTERACTING POLYPEPTIDES AND METHODS OF USE**Serial/Reg./Patent No. **10/782,375**Date Sent: **10/8/2004** Hand Carried Fax Electronic Cert. of Mailing Express Mail No. EV 540 267 677 US Transmittal LetterNew Patent App Utility Design Cont. CIP Div. PCT RCE Prov Other: **Paper Copy of Sequence Listing Pages 1 to 14; A Copy of the Sequence Listing in Computer Readable Form and Statement Under 37 C.F.R. § 1.821(f) and (g)**

pages of Specification
 pages of Claims
 pages of Abstract
 pages of Formal/Informal Drawings

- Req. for Approval of Drawing Amendments
 Req. for Oral Hearing
 Not of Appeal Appeal Brief Reply Brief
 Rule 312 Amendment/Letter
 Req. for Acknowledgement of Cited Art
 Issue Fee
 Publication Fee
 Req. for Certificate of Correction
 Maintenance Fee for _____ years after grant
 Fee Address Indication Form
 Terminal Disclaimer
 Petition to Commissioner
 Status Inquiry
 Other Statement Under 37 C.F.R. § 3.73(b) and a copy of the executed assignment.

Small Entity Statement
 Declaration/Power of Attorney

Recordation of Assignment/Security Agreement
 Information Disclosure Statement

Form PTO 1449

copies of cited references

Preliminary Amendment
 Response to Missing Parts Notice and A Copy of the Missing Parts
 Resp. to Notice to Correct App. Papers
 Certified Copy of Priority Doc.
 Claim for Convention Priority
 Response/Amendment to Office Action of _____
 Request for _____ month Extension of Time

Check for \$	<input checked="" type="checkbox"/> Charge Deposit Acct. 502624\$	716.00	Atty Init.	DLC	Tkpr. #	7312	Secy. or PL:	CCasey
--------------	---	--------	------------	-----	---------	------	--------------	--------

CMS Descrip.: **\$395.00 - Basic Filing Fee****\$65.00 - Surcharge Fee****\$256.00 - excess claims**

THE PATENT AND TRADEMARK OFFICE DATE STAMPED HEREON IS ACKNOWLEDGEMENT THAT THE ITEMS, CHECKED ABOVE, WERE RECEIVED BY THE PTO ON THE DATE STAMPED.



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 12 2005

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/782,375	TRADEMAILED 02/18/2004	Stefan M. Pulst	66783-145

CONFIRMATION NO. 3578

ABANDONMENT/TERMINATION
LETTER



OC000000016019444

Cathryn Campbell
McDERMOTT, WILL & EMERY
7th Floor
4370 La Jolla Village Drive
San Diego, CA 92122

Date Mailed: 05/13/2005

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 08/13/2004.

- No reply was received.

If a complete reply to the notice was previously filed by applicant within the time period set forth in the notice, applicant may request for reconsideration of the holding of abandonment within 2 months from the mailing of this notice of abandonment by filing a petition to withdraw the holding of abandonment under 37 CFR 1.181(a). No petition fee is required. The petition must be accompanied by a true copy of the originally filed reply and the item(s) identified in one of the following:

1. A properly itemized date-stamped postcard receipt (see MPEP § 503);
2. If the originally filed reply included a certificate of mailing or transmission in compliance with 37 CFR 1.8(a), a copy of the certificate of mailing or transmission and a statement in compliance with 37 CFR 1.8(b) (see MPEP §§ 512); or
3. If the reply was filed via Express Mail, a submission satisfying the requirements of 37 CFR 1.10(e) including, for example, a copy of the Express Mail mailing label showing the "date-in" (see MPEP § 513).

Any petition to withdraw the holding of abandonment should be directed to OIPE.

If applicant did not previously file a complete reply within the time period set forth in the notice, applicant may file a petition to revive the application under 37 CFR 1.137.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/61.

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-

identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/64.

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (571) 272-3282.

P13 L

*A copy of this notice **MUST** be returned with the reply.*

Office of Initial Patent Examination (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE